SCHEMBL2262103

SCHEMBL2262103

Cc1cc(C#N)c(Cl)cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.39
AR P10275 3/20 0.39
PGK1 P00558 1/20 0.39
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
G6PD P11413 1/20 0.38
CYP2C9 P11712 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
CCR6 P51684 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27802230 0.92 TRPV4 (0.39) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL18179223 0.82 TRPV4 (0.45) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL2473663 0.80 TSHR (0.52) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL29421170 0.80 TSHR (0.52) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL7714672 0.80 KDM4E (0.48) ARHPGDHSD17B10ALDH1A1CYP3A4
SCHEMBL2131816 0.79 GPR35 (0.44) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL28408336 0.76 TRPV4 (0.43) TRPV4ARPGK1HSD17B10ALDH1A1
SCHEMBL31222234 0.76 TSHR (0.52) TRPV4ARPGK1HPGDHSD17B10
SCHEMBL23754017 0.75 TRPV4 (0.39) TRPV4ARPGK1HSD17B10ALDH1A1
SCHEMBL3338849 0.75 ALDH1A1 (0.42) TRPV4ARPGK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3344619-B1 PHENOXYMETHYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-10-28 EP disclosed
WO-2017037146-A1 PHENOXYMETHYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2017-03-09 WO disclosed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US disclosed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A TRPV4 4671/4885AR 1225/4885PGK1 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.